Study population and data collection
active malignancies, allergy, infection
BRAIN METASTASES, CERVICAL CANCER, ALLERGY, INFECTION
The trial was a single-center, open-label, randomized study at the First Affiliated Hospital of Air Force Medical University (Xi’an, China) and was registered in ClinicalTrials.gov (NCT03206684). Patients were eligible for inclusion if they had cervical cancer with the 2009 International Federation of Gynecology and Obstetrics (FIGO) IB–IVA stage and were intended to receive radical chemoradiotherapy from February 2018 to July 2019. Eligible patients were also required to be aged ≥18 years, have a Karnofsky performance score of ≥70, and have consented to receive radical chemoradiotherapy regimen with docetaxel and cisplatin. The key exclusion criteria included the presence of (1) other active malignancies or brain metastases, (2) existing infection that is difficult to control, or (3) allergy to PEG-rhG-CSF and rhG-CSF or other biologic products derived from genetically engineered 